Ex VIvo DEtermiNed Cancer Therapy

Recruiting now

Conditions studied: Bladder Cancer, Kidney Cancer, Melanoma, Sarcoma, Glioblastoma, Head and Neck Cancer

In brief

EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.

Key facts

Study ID

NCT05231655

Run by

Sheffield Teaching Hospitals NHS Foundation Trust

People needed

600

Starts

2021-07-07

Expected to finish

2027-01-01

Last updated by the study team

2025-02-24

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• >16 years of age with a diagnosis of known or suspected solid cancer who will undergo surgery, biopsy, aspirate, or TURBT
• Willing to donate a section fresh tumour tissue from surgery, a TURBT, fluid aspirate, or biopsy surplus to diagnostic use
• Willing to donate a 9ml blood sample
• Able to give written informed consent
• Previously treated patients are eligible if:
• Present with a recurrence of a previously treated tumour. This may be a local or metastatic recurrence
• Have undergone treatment for their cancer, but fail to respond to this and progress
• Have received neoadjuvant therapy for their tumour
• Have undergone chemotherapy, targeted therapy, immunotherapy, hormone therapy and or radiotherapy for a previous tumour

You may not qualify if…

• Patients with a known diagnosis of a blood borne virus (Hepatitis B, Hepatitis C, HIV). (The laboratories where experiments will be conducted do not have the safety facilities to use material containing these pathogens)
• Patients with a current positive COVID-19 infection

Where it is running

• Sheffield Teaching Hospitals NHS Foundation Trust — Sheffield, South Yorkshire, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.